蛋白激酶B抑制剂capivasertib治疗乳腺癌的研究进展  

Advances in protein kinase B inhibitor capivasertib for breast cancer treatment

作　　者：耿继红 全香花[2] 赵俊[2] 都彩莹 孙彩红 元海丹[1] GENG Ji-hong;QUAN Xiang-hua;ZHAO Jun;DU Cai-ying;SUN Cai-hong;YUAN Hai-dan(School of Pharmacy,Yanbian University,Yanji 133002,China;Department of Pharmacy,Affiliated Hospital of Qingdao University,Qingdao 266003,China)

机构地区：[1]延边大学药学院,延吉133002 [2]青岛大学附属医院药学部,青岛266003

出　　处：《中国新药杂志》2025年第5期483-489,共7页Chinese Journal of New Drugs

基　　金：国家自然科学基金项目(82060674);青岛大学附属医院“临床医学+X”科研项目(QDFY+X2023127)。

摘　　要：capivasertib是一种蛋白激酶B(protein kinase B,AKT)抑制剂,于2023年11月16日由美国FDA正式批准上市。《中国临床肿瘤学会乳腺癌诊疗指南》(2024版)推荐将其作为晚期乳腺癌患者内分泌治疗联合细胞周期蛋白依赖性激酶4/6抑制剂治疗失败的选择,目前国内上市申请正在受理中。capivasertib作为全球首款获批的AKT抑制剂,与氟维司群联用可改善激素受体阳性/人表皮生长因子受体2阴性晚期或转移性乳腺癌患者的中位无进展生存期和总生存期,且安全性好,临床应用前景广阔。Capivasertib,a protein kinase B(AKT)inhibitor,was officially approved by the U.S.FDA on November 16,2023.The 2024 Chinese Society of Clinical Oncology Breast Cancer Diagnosis and Treatment Guidelines recommends it as a treatment option for the failure of endocrine therapy combined with cyclin-dependent kinase 4/6 inhibitor in patients with advanced breast cancer.Currently,the domestic listing application is under review.As the world s first approved AKT inhibitor,capivasertib,in combination with fulvestrant,can improve the median progression-free survival and overall survival of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.It has a good safety profile,thus being a promising application prospect.

关 键 词：capivasertib 乳腺癌 蛋白激酶B抑制剂 

分 类 号：R979.1[医药卫生—药品]